The present study was also able to illustrate the clinical benefit of inhibiting aromatase activity as monitored by the marked reduction (>50%) in tumour volume (assessed by ultrasound) in 18 of the 24 patients (Dixon et al, 2000). The gene discussed is CYP19A1; the disease is neoplasm.